What You Should Know:
– Digital diabetes management tools are failing to deliver meaningful health benefits to patients, according to a new evaluation by the Peterson Health Technology Institute (PHTI).
– The report casts doubt on…
Continue Reading
What You Should Know:
– Ultrahuman, a pioneer in wearable health technology raises $35M in Series B funding led by prominent like Blume Ventures and Steadview Capital.
– Ultrahuman is set to achieve a significant milestone…
Continue Reading
3. Manage the Devices and Network of Your Connected EnvironmentAmong the thousands of identities that healthcare IT teams must manage, they also need to know what devices are accessing their networks. That’s hundreds or…
Continue Reading
Type 1 diabetes (T1D) is a chronic condition characterized by glucose fluctuations. Laboratory studies suggest that cognition is reduced when glucose is very low (hypoglycemia) and very high (hyperglycemia). Until recently, technological limitations prevented…
Continue Reading
An over-the-counter continuous glucose monitoring (CGM) solution developed by Dexcom called Stelo has received clearance from the Food and Drug Administration (FDA).Available without the need for a prescription, the wearable biosensor boasts a battery…
Continue Reading
What You Should Know:
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom – the first glucose biosensor that doesn’t…
Continue Reading
What You Should Know: – Know Labs (NYSE American: KNW), a leading innovator in non-invasive medical diagnostic technology, today announced the unveiling of its KnowU™, a wearable, non-invasive continuous glucose monitor (CGM). – With…
Continue Reading
Pregnant women at University Hospital Southampton NHS Foundation Trust have become the first globally to access the gold standard oral glucose tolerance test through a remote screening initiative.Traditional the screening process for gestational diabetes…
Continue Reading
Medicare’s April 2023 decision to increase coverage for continuous glucose monitoring (CGM) was a major development for diabetes management. Now, with over a million new eligible beneficiaries and many more to follow this year,…
Continue Reading
What You Should Know:
– Medicare has significantly expanded access to the Eversense E3 continuous glucose monitoring (CGM) System, a long-lasting and implantable option that offers several advantages over traditional CGMs.
– Medicare has significantly expanded…
Continue Reading
